

FW: reviewer ASJ

Dari: komang168 (komang168@yahoo.com)

Kepada: yuyunhand@yahoo.com

Tanggal: Kamis, 8 Oktober 2020 13.17 WIB

Sent from my Samsung Galaxy smartphone.


----- Original message -----

From: oen sindrawati <oensindrawati@gmail.com>

Date: 10/8/20 13:40 (GMT+08:00)

To: Komang Agung <komang168@yahoo.com>

Subject: reviewer ASJ

Invitation to Review for Journal of Orthopaedic Surgery 



Journal of Orthopaedic Surgery <onbehalf@manuscriptcentral.com>

Mon, Sep 28, 8:08 AM (2 days ago)



to komang168, me

27-Sep-2020

Dear Dr. Irianto:

Manuscript ID OSJ-20-0611 entitled "Clinical characteristics and outcomes of patients with COVID-19 infection undergoing orthopaedic surgeries" has been submitted to Journal of Orthopaedic Surgery.


I invite you to review this manuscript. The abstract appears at the end of this letter. Please let me know as soon as possible if you will be able to accept my invitation to review. Please click the appropriate link at the bottom of the page to automatically register your reply with our online manuscript submission and review system.

Journal of Orthopaedic Surgery greatly values the work of our reviewers. In recognition of your continued support, we are pleased to announce that we have arranged with our publisher SAGE to offer you free access to all SAGE journals for 60 days upon receipt of your completed review and a 25% book discount on all SAGE books ordered online. We will send you details of how to register for online access and order books at discount as soon as you have submitted your review.

Journal of Orthopaedic Surgery is committed to ensuring that the peer-review process is as robust and ethical as possible. The Committee on Publication Ethics (COPE) guidelines regarding peer review can be found at the following link. Please read the guidelines before accepting or declining my invitation. http://publicationethics.org/files/Ethical_guidelines_for_peer_reviewers_0.pdf

Once you accept my invitation to review this manuscript, you will be notified via e-mail about how to access ScholarOne Manuscripts, our online manuscript submission and review system. You will then have access to the manuscript and reviewer instructions in your Reviewer Center.

Please note the following definitions for MINOR and MAJOR REVISIONS:

Thank you for submitting your review of Manuscript ID OSJ-20-0611 for Journal of Orthopaedic Surgery 



Journal of Orthopaedic Surgery <onbehalf@manuscriptcentral.com>

9:39 PM (1 hour ago)



to komang168, me

30-Sep-2020

Dear Dr. Irianto:

Thank you for reviewing manuscript # OSJ-20-0611 entitled "Clinical characteristics and outcomes of patients with COVID-19 infection undergoing orthopaedic surgeries" for Journal of Orthopaedic Surgery.

In recognition of your continued support, Journal of Orthopaedic Surgery and our publisher SAGE are pleased to offer you 60 days complimentary online access to all journals published by SAGE. Register at <http://journals.sagepub.com/page/help/reviewer-access> to activate access to content from all journals. To also benefit from a 25% discount on all SAGE books ordered online, go to the SAGE website (<http://www.sagepublications.com/>) and add the SAGE books that you would like to purchase to your shopping cart. When checking out, enter the Promotion Code GL10JR0001 when prompted. This will automatically deduct 25% from your final bill.

We are collaborating with Publons to give you the recognition you deserve for your peer review contributions. If you opted in for recognition on Publons when you submitted this review, you will shortly receive an email inviting you to claim your review on the site. If you would like to get credit for your peer review but did not opt in and/or have not yet signed up, you can still do so by registering at <https://publons.com/home/>. Then simply forward this email to reviews@publons.com and the review will be added to your profile.

On behalf of the Editors of Journal of Orthopaedic Surgery, we appreciate the voluntary contribution that each reviewer gives to the Journal. We thank you for your participation in the online review process and hope that we may call upon you again to review future manuscripts.

Sincerely,

Dr. Daisuke Sakai

Associate Editor, Journal of Orthopaedic Surgery



REVIEW FOR OSJ 20.docx

12.4kB



OSJ-20-0611_Proof_hi.pdf
1.4MB



Clinical characteristics and outcomes of patients with COVID-19 infection undergoing orthopaedic surgeries

Journal:	<i>Journal of Orthopaedic Surgery</i>
Manuscript ID	OSJ-20-0611
Manuscript Type:	Original Article
Keywords:	COVID-19, SARS-CoV-2, Orthopaedic, Surgery, Lymphocyte
Abstract:	<p>Background: Coronavirus disease 2019 (COVID-19) is an acute infectious disease caused by a novel coronavirus. Data on the clinical characteristics and outcomes of COVID-19 patients who had undergone orthopaedic surgeries were very limited. The goal of this study was to report the clinical characteristics, complications and outcomes of COVID-19 patients affected by bone fractures and soft tissue injuries.</p> <p>Methods: We retrospectively analyzed the clinical data of eight patients with COVID-19 pneumonia and orthopaedic conditions at our hospital from February 9 to March 20, 2020.</p> <p>Results: The age range of the eight patients was 35 to 87 years. Their common symptoms included fever (50%), cough (100%) and fatigue (37.5%). Two of the eight patients had lymphopenia. Five patients had elevated concentrations of C-reactive protein. All of them had high levels of D-dimer. Five patients had either hip or spinal compression fractures. The CD4+/CD8+ ratio in two patients was less than one. Of the four patients who required orthopaedic surgery, two of them developed fever (range 37.8–38.5°C), while all had reduced lymphocyte counts and elevated concentrations of C-reactive protein after the operation. One patient died of COVID-19 associated complications on postoperative day 9.</p> <p>Conclusions: Stress arising from orthopaedic surgery may accelerate and aggravate the progression of COVID-19, especially for elderly patients. Clinicians should assess the immunological status of the COVID-19 patients at pre-operation, and track both lymphocyte counts and IL-6 levels before and after any operation to monitor patient status and prognosis.</p>

SCHOLARONE™
Manuscripts

1
2
3
4 1 Clinical characteristics and outcomes of patients with COVID-19 infection5
6 2 undergoing orthopaedic surgeries
7
8
9 310
11 4 **Abstract**

12
13
14 5 **Background:** Coronavirus disease 2019 (COVID-19) is an acute infectious disease
15
16
17 6 caused by a novel coronavirus. Data on the clinical characteristics and outcomes of
18
19
20 7 COVID-19 patients who had undergone orthopaedic surgeries were very limited. The
21
22
23 8 goal of this study was to report the clinical characteristics, complications and outcomes
24
25 9 of COVID-19 patients affected by bone fractures and soft tissue injuries.

26
27
28 10 **Methods:** We retrospectively analyzed the clinical data of eight patients with COVID-
29
30
31 11 19 pneumonia and orthopaedic conditions at our hospital from February 9 to March 20,
32
33 12 2020.

34
35
36 13 **Results:** The age range of the eight patients was 35 to 87 years. Their common
37
38 14 symptoms included fever (50%), cough (100%) and fatigue (37.5%). Two of the eight
39
40
41 15 patients had lymphopenia. Five patients had elevated concentrations of C-reactive
42
43
44 16 protein. All of them had high levels of D-dimer. Five patients had either hip or spinal
45
46
47 17 compression fractures. The CD4⁺/CD8⁺ ratio in two patients was less than one. Of the
48
49
50 18 four patients who required orthopaedic surgery, two of them developed fever (range
51
52
53 19 37.8–38.5°C), while all had reduced lymphocyte counts and elevated concentrations of
54
55
56 20 C-reactive protein after the operation. One patient died of COVID-19 associated
57
58
59 21 complications on postoperative day 9.

60 22 **Conclusions:** Stress arising from orthopaedic surgery may accelerate and aggravate the

1
2
3
4 23 progression of COVID-19, especially for elderly patients. Clinicians should assess the
5
6
7 24 immunological status of the COVID-19 patients at pre-operation, and track both
8
9
10 25 lymphocyte counts and IL-6 levels before and after any operation to monitor patient
11
12 26 status and prognosis.
13
14
15
16

17 28 **Keywords:** COVID-19, SARS-CoV-2, Orthopaedic, Surgery, Lymphocyte
18
19
20 29

21 30 **Introduction**

22
23
24
25 31

26
27 32 In December 2019, an outbreak of severe acute respiratory syndrome coronavirus
28
29
30 33 2 (SARS-CoV-2) infection was first reported in Wuhan, Hubei Province, China [1]. It
31
32
33 34 has subsequently been reported in other areas of China and around the world. On
34
35
36 35 February 12, 2020, the World Health Organization officially named the disease caused
37
38 36 by the SARS-CoV-2 as Coronavirus Disease 2019 (COVID-19) and declared it as a
39
40
41 37 Public Health Emergency of International Concern. By April 28, 2020, there were
42
43 38 7,553,182 confirmed cases with 423,349 related deaths from 216 countries [2].
44
45
46 39

47
48 40 Across the globe, many cities have implemented extraordinary measures to restrict
49
50
51 41 the spread of the virus and were in “lockdown”. In order to utilize the limited resources
52
53
54 42 for managing the COVID-19 pandemic, “elective” surgery has been largely postponed
55
56 43 and stopped [3,4]. However, some patients affected by bone fractures or soft tissue
57
58
59 44 injury still needed surgery. Previous studies have reported the clinical characteristics
60

1
2
3
4 45 and early prognosis of ten COVID-19 patients with fracture [5]. The surgeries
5
6 46 performed on those patients were unintentional and were not planned, and the
7
8
9 47 conditions of those patients with fracture were more severe than those without fracture.
10
11 48 At the present, the clinical characteristics, surgical risk and outcomes of the COVID-
12
13
14 49 19 patients undergoing planned orthopaedic surgery operations remained unknown.
15
16
17 50 Herein, we retrospectively collected and analyzed detailed clinical data from eight
18
19
20 51 orthopaedic patients with COVID-19 infection admitted to our hospital. The objective
21
22 52 of this study was mainly to describe treatment outcomes among patients undergoing
23
24 53 planned orthopaedic surgery at the time of SARS-CoV-2 infection. Findings of the
25
26
27 54 SARS-CoV-2 associated postoperative morbidity and mortality from this study can
28
29
30 55 inform and benefit the global community in the battle against COVID-19.
31
32
33 56

35 57 **Methods**

38 58 39 40 59 **Study design and patients**

41
42
43 60
44
45 61 We conducted a retrospective review of medical records on eight patients with
46
47
48 62 COVID-19 pneumonia and orthopaedic conditions admitted to our hospital from
49
50
51 63 February 9 to March 20, 2020. Diagnosis of COVID-19 pneumonia was based on the
52
53
54 64 New Coronavirus Pneumonia Prevention and Control Program (6th edition) published
55
56
57 65 by the National Health Commission of China [6]. Six patients with COVID-19
58
59
60 66 pneumonia tested positive for SARS-CoV-2 by using quantitative RT-PCR (qRT-PCR)

1
2
3
4 67 from throat swab samples. The other two COVID-19 patients were laboratory
5
6 68 confirmed by the presence of positive IgM/IgG anti-SARS-CoV-2 antibody. All
7
8
9 69 patients presented with ground-glass opacities on chest computed tomography (CT)
10
11
12 70 scans.

13 14 71 15 16 17 72 **Data collection**

18
19 73
20
21
22 74 We reviewed clinical records, laboratory test results, chest CT scans, treatment and
23
24 75 clinical outcomes for all eight patients. All information was organized and recorded on
25
26 76 a customized data collection form. The throat swab samples were collected and tested
27
28 77 for SARS-CoV-2 using the Chinese Center for Disease Control and Prevention
29
30 78 recommended Kit (BioGerm, Shanghai, China), following the WHO guidelines for
31
32 79 qRT-PCR [7,8]. All samples were processed at the Department of Clinical Laboratory
33
34 80 of our hospital. Primers were designed based on the sequence of Wuhan-Hu-1
35
36 81 (MN908947). Partial S segment sequences (nt 21730-22458) were amplified with
37
38 82 primers: 5'-CTCAGGACTTGGTCTTACCTT-3' and 5'-
39
40 83 CAAGTGCACAGTCTACAGC-3'.

41 42 43 44 45 84 46 47 48 49 50 85 **Statistical analyses**

51
52
53 86
54
55
56 87 Data were analyzed using standard descriptive statistics as appropriate.
57
58 88 Continuous variables were directly expressed as a range. Categorical variables were
59
60

1
2
3
4 89 reported as count and proportion. All statistical analyses were conducted using the
5
6 90 SPSS software version 23.0 (Chicago, IL., USA). Diagrams were drawn using the Prism
7
8
9 91 software version 8.0 (San Diego, CA., USA).
10
11
12 92

13 14 93 **Results**

15
16
17 94
18
19 95 All patients were residents of Wuhan City in China and had a history of exposure to
20
21
22 96 COVID-19. Among them, six confirmed of COVID-19 via positive SARS-CoV-2
23
24
25 97 nucleic acid test, and two diagnosed with COVID-19 by positive IgM/IgG anti-SARS-
26
27
28 98 CoV-2 antibody. Additionally, five patients tested positive on the anti-SARS-CoV-2
29
30
31 99 antibody IgG test. However, none of the eight patients was negative for both the
32
33 100 COVID-19 antibody and SARS-CoV-2 nucleic acid tests.
34

35 101 The age range of the patients was 35 to 87 years. Seven patients had bone fractures,
36
37
38 102 and one patient was referred to our hospital for surgical treatment of lower extremity
39
40
41 103 ischemia and necrosis. Five of the seven patients with hip fracture or spinal
42
43
44 104 compression fracture demonstrated that osteoporosis was the main cause of fracture.

45 105 All elderly patients had underlying diseases such as chronic obstructive pulmonary
46
47
48 106 disease, chronic hypertension, malignancy, cerebrovascular disease and rheumatoid
49
50
51 107 arthritis.

52
53 108 Four of the eight patients were presented with a fever without chills, but none of them
54
55
56 109 had high fever (body temperature $>39^{\circ}\text{C}$). Eight patients (100%) had a cough, three
57
58
59 110 patients (37.5%) reported myalgia and fatigue, and two (25%) reported a sore throat.
60

1
2
3
4 111 Additionally, one (12.5%) patient showed dyspnea and chest pain. None of them had
5
6 112 diarrhea.

7
8
9 113 Results from laboratory tests showed that two of the eight patients had a white cell
10
11 114 count below the normal range and had lymphopenia. Five patients had elevated
12
13 115 concentrations of C-reactive protein (CRP). Four patients had increased concentrations
14
15 116 of alanine aminotransferase and aspartate aminotransferase. Additionally, due to
16
17 117 restriction of activities, all of the patients had high level of D-dimer (table 1). All eight
18
19 118 patients had a chest CT scan, and showed multiple patchy ground-glass shadows in their
20
21 119 lungs (figure 1).

22
23
24
25
26
27 120 To evaluate the immune function of the patients, we examined the lymphocyte
28
29 121 subsets. We found the the $CD4^+/CD8^+$ ratio in patient 3 and 7 was 0.45 and 0.95
30
31 122 respectively (table 2).

32
33
34
35 123 Four patients underwent orthopaedic surgery (figure 2). Before surgery, all four
36
37 124 patients were in a stable condition with no fever and dyspnea. One patient had cough,
38
39 125 but this patient's phlegm culture was negative. Two patients received general anesthesia,
40
41 126 and the other two received spinal anesthesia. After surgery, all patients were given
42
43 127 oxygen support, antiviral therapy and empirical antibiotic treatment (table 3). Two
44
45 128 patients later developed fever (range 37.8–38.5°C) during the postoperative period. The
46
47 129 lymphocyte count was further reduced and the concentrations of CRP were significantly
48
49 130 elevated for all patients after the operation (figure 3). However, patient 3 showed
50
51 131 increasing levels of inflammatory cytokine progressively, and he was presented with
52
53 132 acute myocardial infarction, which progressed rapidly to multisystem organ failure.
54
55
56
57
58
59
60

1
2
3
4 133 Unfortunately, he died nine days after the operation. The remaining three surgical
5
6
7 134 patients were discharged at 11, 15, 17 days after surgery, respectively.

8
9 135 There were four non-surgical patients. Their age ranged from 80 to 87 years old.
10
11
12 136 They each received conservative treatment and by the end of April 3, 2020, two patients
13
14
15 137 had been discharged but two were still in the hospital.

16
17 138 Higher than normal levels of serum cytokine (IL-6) were detected in all eight patients,
18
19
20 139 particularly in patient 3 who died after surgery. The plasma concentration of IL-6 in
21
22
23 140 patient 3 was 336.2 pg/mL (normal value ≤ 7 pg/mL) (table 2). Patient 3's leukopenia
24
25
26 141 persisted and inflammation intensified (CRP 189.95 mg/l) (figure 3).

27 142
28
29
30 143 **Discussion**

31
32 144
33
34
35 145 In the midst of the COVID-19 pandemic, healthcare providers are struggling to
36
37
38 146 understand how to properly respond and treat COVID-19 patients with orthopaedic
39
40
41 147 conditions. To shed light on the treatment options of COVID-19, we present clinical
42
43
44 148 findings from eight patients with COVID-19 pneumonia who were hospitalized in an
45
46
47 149 orthopaedic unit in China. The clinical characteristics of these patients were similar to
48
49
50 150 those of non-fracture patients with COVID-19 infection, as previously reported in the
51
52
53 151 literature [9]. Four of the eight patients underwent surgical treatment, and all of the four
54
55
56 152 patients showed elevated inflammatory markers and decreased lymphocytes after
57
58
59 153 surgery, with one patient died of multiple organ failure. The remaining four non-
60
154 surgical patients had advanced age and severe underlying diseases, thus they were

1
2
3
4 155 treated conservatively. None of the four non-surgical patients developed severe
5
6 156 pneumonia nor died, as of April 4, 2020. Notably, based on the findings of these eight
7
8
9 157 patients, there was evidence to suggest that surgical stress could lead to occurrence of
10
11
12 158 severe adverse outcomes in the COVID-19 patients, especially in the elderly.

13
14 159 People are generally susceptible to COVID-19. The elderly patients and those with
15
16
17 160 underlying diseases can be affected even more seriously [10]. Since the elderly patients
18
19
20 161 are particularly susceptible to osteoporosis, they are more likely to develop fragility
21
22 162 fracture [11]. In this study, we treated seven patients who had bone fractures, with three
23
24
25 163 of them having hip fracture and two having vertebral compression fracture. Five elderly
26
27 164 patients developed fractures during the treatment for COVID-19 pneumonia, which
28
29
30 165 could be explained by the fact that the COVID-19 patients were more prone to falls due
31
32
33 166 to a weak physical health state, and their long-term bedridden treatment could lead to
34
35
36 167 more severe osteoporosis. Therefore, it is necessary to take adequate measures to
37
38 168 prevent fracture in elderly patients with COVID-19 pneumonia [12].

39
40 169 Elderly patients with hip fractures are at risk for cardiovascular, pulmonary,
41
42
43 170 thrombotic, infectious, and bleeding complications [13]. These complications can result
44
45
46 171 in death. Therefore, performing timely surgery for these patients remains the mainstay
47
48
49 172 of treatment. However, surgical procedures can also pose risks to the COVID-19
50
51
52 173 pneumonia patients, especially for the elderly. During the outbreak of SARS, a geriatric
53
54
55 174 patient with a hip fracture was reported dead seven days after surgery [14]. A recent
56
57
58 175 study showed that 7 out 34 surgical patients (20.6%) died from COVID-19 related
59
60 176 complications [15]. These findings suggest that stress arising from surgery may

1
2
3
4 177 accelerate and aggravate the progression of COVID-19. In addition, the Centers for
5
6 178 Disease Control and Prevention in the United States reported that 80% of COVID-19
7
8
9 179 deaths were observed in adults 65 years or older [16] and that the patients were still
10
11 180 required to stay in hospitals after the surgery to treat pneumonia. As such,
12
13
14 181 comprehensive strategies that take into account of conservative treatment measures for
15
16
17 182 elderly patients are needed. After the COVID-19 is cured, a second stage of operation
18
19
20 183 could be further considered. On the other hand, for younger patients who have no
21
22 184 serious underlying disease, a joint consultation with anesthesiologist, respiratory
23
24
25 185 doctors and intensive care unit doctors is recommended to ensure patient safety before
26
27
28 186 and after surgery.

29
30 187 Research has shown that SARS-CoV-2 mainly acts on lymphocytes to induce a
31
32 188 cytokine storm in the body and generate a series of immune responses, resulting in
33
34
35 189 leukopenia. Thus, a patient's immune function plays an important role in fighting off
36
37
38 190 the SARS-CoV-2 infection [10]. Lymphocyte count and lymphocyte subset are of great
39
40
41 191 value to ensure immune system functionality. Studies have demonstrated that the
42
43 192 CD4⁺/CD8⁺ ratio of less than 1 is linked to immune senescence and all-cause mortality
44
45
46 193 [17,18]. Moreover, in HIV patients, having a low CD4⁺ percentage and a low
47
48
49 194 CD4⁺/CD8⁺ ratio prior to the initiation of antiretroviral therapy is predictive of the risk
50
51
52 195 of adverse clinical progression [19]. Of note, CD4⁺ and CD8⁺ counts reflect the severity
53
54
55 196 of infection and may predict the clinical outcomes in patients with COVID-19 [20-22].
56
57
58 197 In the present study, patient 3 had a low CD4⁺ percentage and his CD4⁺/CD8⁺ ratio was
59
60 198 0.45 preoperatively, which were indicative of his low immune function before surgery.

1
2
3
4 199 Having low immune system function likely explains why he developed rapid disease
5
6 200 progression of COVID-19 after surgery. Thus, the CD4⁺/CD8⁺ ratio may be used as a
7
8
9 201 biomarker to identify patients with the worst prognosis, and the immunological status
10
11 202 of the COVID-19 patients should be considered when selecting treatment options for
12
13
14 203 them.

15
16
17 204 Surgery not only can damage the immune system [23], but also can induce the body
18
19 205 to produce an inflammatory response [24]. The high levels of circulating inflammatory
20
21 206 cytokines and the progressively decline of lymphocytes have been reported to correlate
22
23 207 with the severity of COVID-19 [6,9]. Recent research has shown that the increased
24
25 208 amounts of proinflammatory cytokines in serum, in particular IL-6, may drive the
26
27 209 deleterious consequences of the infection [25]. Consistent with these findings, all of the
28
29 210 four patients who underwent surgical treatment in this study had experienced further
30
31 211 lymphocytic decline and increased levels of inflammatory cytokines after surgery. One
32
33 212 (25%) patient died of multiple organ failure nine days after operation. Of importance,
34
35 213 this patient's leukopenia and inflammatory marker elevation persisted (lymphocyte
36
37 214 0.45×10^9 /L, CRP 151.4 mg/L, IL-6 336.2 pg/mL) postoperatively. His condition
38
39 215 progressed rapidly with acute respiratory distress syndrome and acute myocardial
40
41 216 infarction which eventually followed by multiple organ failure. Therefore, evaluation
42
43 217 of the immune system function of the COVID-19 patients is critical and can help
44
45 218 physicians to identify patients with potential poor prognosis. Additionally, early
46
47 219 identification and timely treatment of lymphopenia are important in the postoperative
48
49 220 care of the COVID-19 patients.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 221 In summary, we described the clinical characteristics and outcomes of patients with
5
6 222 COVID-19 infection who underwent orthopaedic surgery. Although our conclusions
7
8
9 223 are limited by the small sample size, we believe that the findings reported here are
10
11 224 important for management of orthopaedic patients. Clinicians should consider tracking
12
13
14 225 both the lymphocyte count and IL-6 during the postoperative period to monitor patient
15
16
17 226 status and prognosis. Risk factors for the poor prognosis of orthopaedic operative
18
19
20 227 patients with COVID-19 need to be further studied.
21
22
23
24

228

229 **Abbreviations**

230 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; COVID-19:
231 Coronavirus Disease 2019; CRP: C-reactive protein; COPD: chronic obstructive
232 pulmonary disease; ALT: alanine aminotransferase; AST: Aspartate aminotransferase.
233

234

234 **Acknowledgments**

235 We would like to thank all the patients involved in our investigation, and the many
236 colleagues who offered their constructive opinions.
237

238

238 **Authors' contributions**

239 YL and YL-L conceived and conceptualized the study. YL-L drafted the manuscript
240 with help from LF, WT, and MH. YL-C and YL-L helped in the statistical analyses.
241 Statistical analysis was discussed with YL-L, ZW-S, WT and YL. YL, MH, and LF
242 contributed to the revision. All authors were involved in the editing the article, and

1
2
3
4 243 agree on the final version.
5
6

7 244
8

9 245 **Funding**
10

11 246 This work was supported by grants from the National Natural Science Foundation of
12
13
14 247 China (No. 81702157).
15
16

17 248
18

19 249 **Availability of data and materials**
20

21
22 250 The raw data supporting the conclusions of this article will be made available by the
23
24
25 251 authors, without undue reservation.
26

27 252
28

29
30 253 **Ethics approval and consent to participate**
31

32 254 The studies involving human participants were reviewed and approved by the Ethics
33
34
35 255 Commission of the Wuhan Union Hospital. Written informed consent for participation
36
37
38 256 was not required for this study in accordance with the national legislation and the
39
40 257 institutional requirements.
41

42 258
43

44
45 259 **Consent for publication**
46

47
48 260 Not applicable.
49

50 261
51

52
53 262 **Competing interests**
54

55
56 263 The authors declare that they have no competing interests.
57

58 264
59
60

265 **References**

- 266 1. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a
267 group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of
268 Wuhan, China: retrospective case series. *Bmj*. 2020;368:m606. doi: 10.1136/bmj.m606.
- 269 2. Coronavirus disease 2019 (COVID-19): situation report, Geneva:World Health
270 Organization, (2020) Available online at:
271 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. (accessed 13 june
272 2020).
- 273 3. Iacobucci G. Covid-19: all non-urgent elective surgery is suspended for at least three
274 months in England. *BMJ*. 2020;368:m1106. doi: 10.1136/bmj.m1106.
- 275 4. Coimbra R, Edwards S, Kurihara H, Bass GA, Balogh ZJ, Tilsed J, et al. European
276 Society of Trauma and Emergency Surgery (ESTES) recommendations for trauma and
277 emergency surgery preparation during times of COVID-19 infection. *Eur J Trauma
278 Emerg Surg*. 2020;46(3):505-10. doi: 10.1007/s00068-020-01364-7.
- 279 5. Mi B, Chen L, Xiong Y, Xue H, Zhou W, Liu G. Characteristics and Early Prognosis
280 of COVID-19 Infection in Fracture Patients. *J Bone Joint Surg Am*. 2020;102(9):750-
281 8. doi: 10.2106/JBJS.20.00390.
- 282 6. National Health Commission of China. The State Council's joint prevention and
283 control mechanism for pneumonia epidemic in response to new coronavirus infection
284 (6th edition). Chinese. Available online at:
285 <http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtm>
286 1. (accessed 2020 Mar 7).

- 1
2
3
4 287 7. WHO. Clinical management of severe acute respiratory infection when novel
5
6 288 coronavirus (nCoV) infection is suspected. Interim guidance. (2020). Available online
7
8
9 289 at: [https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf)
10
11 novel-cov.pdf. (accessed Feb 4, 2020).
12
13
14 291 8. WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected
15
16 292 human cases. Interim guidance. (2020). Available online at:
17
18
19 293 [https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)
20
21 coronavirus-in-suspected-human-cases-20200117. (accessed Feb 4, 2020).
22
23
24 295 9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
25
26 296 infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*.
27
28 297 2020;395(10223):497-506. doi: 10.1016/s0140-6736(20)30183-5.
29
30
31 298 10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
32
33 299 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
34
35 300 descriptive study. *The Lancet*. 2020;395(10223):507-13. doi: 10.1016/s0140-
36
37 301 6736(20)30211-7.
38
39
40 302 11. Haentjens P, Autier P, Collins J, Velkeniers B, Vanderschueren D, Boonen S. Colles
41
42 303 fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-
43
44 304 analysis. *J Bone Joint Surg Am*. 2003;85(10):1936-1943. doi:10.2106/00004623-
45
46 305 200310000-00011.
47
48
49 306 12. Zhu Y, Chen W, Xin X, Yin Y, Hu J, Lv H, et al. Epidemiologic characteristics of
50
51 307 traumatic fractures in elderly patients during the outbreak of coronavirus disease 2019
52
53 308 in China. *Int Orthop*. 2020. doi: 10.1007/s00264-020-04575-0.
54
55
56
57
58
59
60

- 1
2
3
4 309 13. Bhandari M, Swiontkowski M. Management of Acute Hip Fracture. *N Engl J Med.*
5
6 310 2017;377(21):2053-62. doi: 10.1056/NEJMcp1611090.
7
8
9 311 14. Wong KC, Leung KS, Hui M. Severe acute respiratory syndrome (SARS) in a
10
11 312 geriatric patient with a hip fracture. A case report. *J Bone Joint Surg Am.*
12
13 313 2003;85(7):1339-1342. doi:10.2106/00004623-200307000-00022.
14
15
16
17 314 15. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and
18
19 315 outcomes of patients undergoing surgeries during the incubation period of COVID-19
20
21 316 infection. *Eclinical Medicine.* 2020;100331. doi: 10.1016/j.eclinm.2020.100331.
22
23
24
25 317 16. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus (COVID-19).
26
27 318 (2020). Available online at: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html)
28
29 319 [precautions/older-adults.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html). (accessed 2020 April 9).
30
31
32 320 17. Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, et al.
33
34 321 Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage
35
36 322 predicting mortality and an increased number of dysfunctional cytomegalovirus-
37
38 323 specific T cells in the very elderly. *J Immunol.* 2006;176(4):2645-2653.
39
40 324 doi:10.4049/jimmunol.176.4.2645.
41
42
43
44
45 325 18. Bruno G, Saracino A, Monno L, Angarano G. The Revival of an "Old" Marker:
46
47 326 CD4/CD8 Ratio. *AIDS Rev.* 2017;19(2):81-88.
48
49
50
51 327 19. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastrì E, et al.
52
53 328 CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV
54
55 329 who achieve viral load suppression with antiretroviral therapy: an observational cohort
56
57 330 study. *The Lancet HIV.* 2015;2(3):e98-e106. doi: 10.1016/s2352-3018(15)00006-5.
58
59
60

- 1
2
3
4 331 20. Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte subset (CD4+,
5
6 332 CD8+) counts reflect the severity of infection and predict the clinical outcomes in
7
8
9 333 patients with COVID-19. *Journal of Infection*. 2020. doi: 10.1016/j.jinf.2020.03.054.
10
11
12 334 21. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients
13
14 335 with COVID-19 in Shanghai, China. *J Infect*. 2020;80(5):e1-e6. doi:
15
16 336 10.1016/j.jinf.2020.03.004.
17
18
19 337 22. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
20
21 338 immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*.
22
23 339 2020; 130(5):2620-9. doi: 10.1172/JCI137244.
24
25
26
27 340 23. Amodeo G, Bugada D, Franchi S, Moschetti G, Grimaldi S, Panerai A, et al.
28
29 341 Immune function after major surgical interventions: the effect of postoperative pain
30
31 342 treatment. *J Pain Res*. 2018; 11:1297-305. doi: 10.2147/JPR.S158230.
32
33
34
35 343 24. Ni Choileain N, Redmond HP. Cell response to surgery. *Arch Surg*.
36
37 344 2006;141(11):1132-1140. doi:10.1001/archsurg.141.11.1132.
38
39
40 345 25. Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F. Exploring the
41
42 346 Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar
43
44 347 Future Global Health Threats. *Cells*. 2020;9(4). doi: 10.3390/cells9040909.

47
48 348 **Figure legends**

49
50 349
51
52
53 350 **Figure 1** Computed tomography of the chest of eight patients with COVID-19. All
54
55 351 patients had bilateral ground-glass opacity and subsegmental areas of consolidation.

56
57
58 352 Fig. 1-A patient 1, Fig. 1-B patient 2, Fig. 1-C patient 3, Fig. 1-D patient 4, Fig. 1-E

1
2
3
4 353 patient 5, Fig. 1-F patient 6, Fig. 1-G patient 7, Fig. 1-H patient 8.
5
6
7 354

8
9 355 **Figure 2** Radiographic images and photographs of the four patients underwent surgery.

10
11 356 Fig. 2-A patient 2. Preoperative and postoperative CT scans showing T12 、 L1

12
13
14 357 vertebral fracture, Fig. 2-B patient 3. Preoperative and postoperative photographs

15
16
17 358 showing right lower limb ischemic necrosis, Fig. 2-C patient 4. Preoperative and

18
19
20 359 postoperative radiographs of the patient with bilateral calcaneal fracture. Fig. 2-D

21
22 360 patient 6. Preoperative and postoperative radiographs of the patient with a femoral neck

23
24
25 361 fracture.
26

27 362

28
29
30 363

31
32 364 **Figure 3** Laboratory characteristics of the four operative patients before and after

33
34
35 365 surgery. (A) The change of postoperative white blood cells. The white blood cell count

36
37 366 increased significantly after the operation. (B) The change of postoperative lymphocyte

38
39
40 367 percentage. The percentage of lymphocytes decreased after surgery. (C) The change of

41
42
43 368 lymphocyte count at post-operation. The lymphocyte count decreased after operation.

44
45
46 369 (D) The change of C- reactive protein at post-operation. The C- reactive protein


47
48 370 increased significantly after the operation. (E) The change of lymphocyte count in

49
50
51 371 patient 3 after operation. His lymphocyte count continued to decline at post-operation.

52
53 372 (F) The change of C- reactive protein in patient 3 after operation. The values of C-


54
55
56 373 reactive protein continued to increase at post-operation.
57

58 374
59
60




Computed tomography of the chest of eight patients with COVID-19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Radiographic images and photographs of the four patients underwent surgery.



Laboratory characteristics of the four operative patients before and after surgery.

Table 1. Clinical presentation and pertinent laboratory findings of the patients with COVID-19.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	n (%)
Date of admission	Feb.9	Feb.18	Feb.20	Feb.21	Feb.21	Feb.27	Feb.29	Mar.3	
Age (years)	81	41	70	35	80	63	87	82	
Gender	Female	Male	Male	Male	Male	Female	Male	Female	
Epidemiological history	exposure to relevant environment	exposure to relevant environment	exposure to relevant environment	exposure to relevant environment	contact with infected person	contact with infected person	exposure to relevant environment	exposure to relevant environment	8(100%)
orthopaedic diagnosis	L2 vertebral compression fracture	T12, L1 vertebral fracture	Right lower limb ischemic necrosis	Bilateral calcaneal fracture	Left femoral neck fracture	Left femoral neck fracture	Right femoral neck fracture	T12 vertebral compression fracture	
Complications	chronic bronchitis	No	Postoperative lung cancer	No	Diabetes, Cerebrovascular disease	rheumatoid arthritis	COPD, hypertension	Cerebrovascular disease	
operation	No	Yes	Yes	Yes	No	Yes	No	No	4(50%)
Signs and symptoms									
Fever	No	No	Yes	Yes	No	Yes	No	Yes	4(50%)
Myalgia	Yes	Yes	Yes	No	No	No	No	No	3(37.5%)
Fatigue	Yes	No	Yes	No	No	Yes	No	No	3(37.5%)
Rigor	No	No	No	No	No	No	No	No	0(0%)
Cough	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	8(100%)
Dyspnoea	No	No	No	No	No	No	No	Yes	1(12.5%)
Sore throat	No	Yes	No	Yes	No	No	No	No	2(25%)
Diarrhoea	No	No	No	No	No	No	No	No	0(0%)
Chest pain	No	No	No	No	No	No	No	Yes	1(12.5%)
Laboratory characteristics									
White blood cell count ($\times 10^9$ cells per L)	4.51	11.89	9.83	11.4	11.5	7.47	11.57	8.24	
Low or normal leukocyte count ($<9.5 \times 10^9$ cells)	Yes	No	No	No	No	Yes	No	No	2(25%)

per L)									
Lymphocyte count ($\times 10^9$ cells per L)	1.13	1.69	1.32	3.02	0.57	1.01	0.49	1.58	
Lymphopenia ($<10^9$ cells per L)	No	No	No	No	Yes	No	Yes	No	2(25%)
C-reactive protein concentration (mg/L)	8.47	0.47	79.08	61.42	105.04	68.7	109.97	3.25	
Elevated C-reactive protein (>10 mg/L)	No	No	Yes	Yes	Yes	Yes	Yes	No	5(62.5%)
ALT (U/L)	36	24	68	62	19	86	17	18	
AST (U/L)	24	17	65	51	39	48	18	28	
Elevated ALT (>45 U/L) or AST (>35 U/L)	No	No	Yes	Yes	No	Yes	No	No	4(50%)
D-dimer concentration	3.6	1.26	6.55	3.5	1.49	6.35	8.5	0.66	
Elevated D-dimer (> 0.5 mg/L)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	8(100%)
COVID-19 Ig G	Positive	Negative	Positive	Positive	Negative	Positive	Positive	Negative	5(62.5%)
COVID-19 Ig M	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	3(37.5%)
Confirmatory test done (SARS-CoV-2 quantitative RT-PCR)	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Positive	6(75%)
CT evidence of pneumonia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	8(100%)

COPD, chronic obstructive pulmonary disease; ALT, alanine aminotransferase; AST, Aspartate aminotransferase.

Table 2. Lymphocyte subset percentage and IL-6 of the eight patients with COVID-19.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8
IL-6(pg/mL)	7.46	9.93	336.2	7.89	28.32	19.82	23.37	132.81
T lymphocytes (%)	75.78	76.14	78.01	80.36	84.5	70.24	76.97	71.09
CD4 ⁺ T (%)	50.74	41.1	26.45	45.28	47.72	49.21	36.02	42.9
CD8 ⁺ T (%)	20.97	30.12	48.7	26.24	35.08	19.53	37.9	24.21
CD4 ⁺ /CD8 ⁺	2.42	1.36	0.54	1.73	1.36	2.52	0.95	1.77

For Peer Review

Table 3. Characteristics of the operative patients with COVID-19 infection.

	Patient2	Patient3	Patient4	Patient6	n (%)
Onset to operation (days)	5	1	18	8	
Preoperative symptoms and signs					
Fever	No	No	No	No	0(0%)
Cough	No	Yes	No	No	1(25%)
Dyspnea	No	No	No	No	0(0%)
Orthopaedic surgery	Open reduction and internal fixation via posterior approach	hip disarticulation	Open reduction and internal fixation	Closed reduction and internal fixation	
anesthesia method	general anesthesia	general anesthesia	spinal anesthesia	spinal anesthesia	
Post-operative symptoms and signs					
Fever	No	Yes	No	Yes	2(50%)
Cough	No	Yes	No	No	1(25%)
Dyspnea	No	Yes	No	No	1(25%)
Treatment after operation					
Oxygen support	Yes	Yes	Yes	Yes	8(100%)
Antiviral therapy	Yes	Yes	Yes	Yes	8(100%)
Antibiotic therapy	Yes	Yes	Yes	Yes	8(100%)
Use of corticosteroid	No	No	No	No	0(0%)
outcome	Getting better and discharged	Death	Getting better and discharged	Getting better and discharged	